Context Therapeutics Inc. Receives Nasdaq Delisting Notice for Non-Compliance with Minimum Bid Price Rule
Philadelphia, PA – July 31, 2026: Context Therapeutics Inc. (NASDAQ: CNTX), a clinical-stage biopharmaceutical company focused on novel cancer therapies, announced today that it has received a written notice from the Nasdaq Listing Qualifications Department notifying the Company that it is not in compliance with Nasdaq Listing Rule 5550(a)(2), commonly known as the “Minimum Bid Price Rule.”
Key Points from the Nasdaq Notification
- Non-Compliance Triggered: The Company’s common stock failed to maintain a minimum closing bid price of \$1.00 per share for 30 consecutive business days, which is a requirement for continued listing on the Nasdaq Capital Market.
- No Immediate Effect: The receipt of this notification does not immediately affect the listing or trading of Context Therapeutics’ common stock. Shares will continue to trade under the ticker symbol “CNTX” on Nasdaq.
- 180 Calendar Days to Regain Compliance: The Company now has an initial period of 180 calendar days, until January 25, 2027, to regain compliance with the Minimum Bid Price Rule. To regain compliance, the closing bid price of the Company’s common stock must be at least \$1.00 per share for a minimum of 10 consecutive business days during this period. Nasdaq reserves the right to extend this 10-day period at its discretion.
- Potential for an Additional Compliance Period: If Context Therapeutics does not regain compliance by January 25, 2027, it may be eligible for an additional 180-day compliance period (the “Second Compliance Period”), provided it meets all other Nasdaq initial listing requirements except for the Minimum Bid Price Rule and notifies Nasdaq of its intent to cure the deficiency.
- Delisting Risk: If the Company fails to regain compliance during the allotted period(s) and does not qualify or is unable to cure the deficiency, Nasdaq will issue a written notice indicating that the Company’s common stock will be subject to delisting. The Company would then have the right to appeal this decision to a Nasdaq Hearings Panel, though there is no assurance such an appeal would succeed.
Implications for Shareholders
- Price-Sensitive Event: The potential for delisting is a material, price-sensitive event that may affect the value of CNTX shares. Delisting from Nasdaq typically reduces liquidity and can negatively impact investor perception and the Company’s ability to raise capital.
- Active Monitoring: Context Therapeutics stated it intends to actively monitor the closing bid price of its common stock and evaluate available options to resolve the deficiency and regain compliance with Nasdaq requirements. However, there can be no assurance that the Company will be able to do so within the applicable timeframes.
- Forward-Looking Risks: The Company cautioned that forward-looking statements regarding regaining compliance are subject to risks and uncertainties, including the risk of not regaining compliance or failing to obtain relief from delisting even if requested. Investors should review the Company’s latest Annual Report on Form 10-K and other SEC filings for additional risk factors.
- Corporate Governance: The notice was signed by Chief Executive Officer Martin A. Lehr, indicating direct oversight and acknowledgment of the situation by senior management.
Summary Table
| Event | Details |
|---|---|
| Nasdaq Listing Rule | Rule 5550(a)(2) – Minimum \$1.00 bid price for 30 consecutive business days |
| Initial Compliance Period | 180 calendar days (until January 25, 2027) |
| Potential Second Compliance Period | Additional 180 days possible, subject to meeting other requirements |
| Delisting Process | Written notice from Nasdaq, right to appeal, no assurance of successful appeal |
| Current Status | Shares remain listed and trading on Nasdaq as “CNTX” |
What Investors Should Consider
This development is highly material for shareholders as it directly impacts the Company’s ability to remain listed on a major U.S. stock exchange and may constrain future financing and liquidity. The Company’s efforts to regain compliance, such as potential reverse stock splits or other corporate actions, may also have significant effects on share value and investor returns.
Forward-Looking Statement Disclaimer
This article contains forward-looking statements based on current expectations and information provided by Context Therapeutics Inc. Actual results and events may differ materially due to various risks and uncertainties, including, but not limited to, the Company’s ability to regain compliance with Nasdaq listing standards, broader market conditions, and Company-specific factors. Investors are advised to review the Company’s filings with the SEC and consult their financial advisors before making investment decisions. This article is not investment advice.
